The challenge of registering Jordanian medicines in Egypt has remained stagnant for over a decade, awaiting definitive solutions. Despite ongoing discussions within joint committees between the two nations, including the recent session of the Supreme Committee held in Amman just two days ago, a resolution is yet to be reached.

In high-level meetings, the Prime Ministers of Jordan and Egypt have emphasized the collaborative nature of their pharmaceutical industries, highlighting that the two countries complement rather than compete with each other for mutual benefit.

Tthe Head of the Federation of Pharmaceutical Producers Wassim Al-Najmi underscored the obstacles stemming from Egypt's stringent registration policies. The lack of reciprocal arrangements, along with a tendency to disregard decisions made during higher committee meetings, has contributed to the problem.

Najmi outlined some of the specific challenges facing the registration process for Jordanian medicines in Egypt. These include exorbitant registration fees amounting to USD 20,000 for each classification, stringent limitations on eligible alternatives for registration, lengthy registration timelines spanning years, as well as stringent export quantities and specific medication requirements.

In contrast, the Jordanian market remains receptive to Egyptian pharmaceuticals. Notably, the selling price of Egyptian medicines in Jordan surpasses their original cost by over fivefold. This exception was granted in 2005.

Statistical data highlights the stark contrast between Jordan's modest pharmaceutical exports, amounting to around USD 10 million, and the substantial Egyptian market, which imports approximately USD 6 million worth of Jordanian pharmaceuticals.